Global Post Acute Myocardial Infarction Market, By Drug Class (Antiplatelet Therapy, Beta Blockers, Renin-Angiotensin-Aldosterone System Inhibitors, Statin Therapy, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Post Acute Myocardial Infarction Market Analysis and Size
The global post acute myocardial infarction market is expected to witness huge growth in the forecast period. Rising cases of hypertension and other cardiovascular diseases boosts the post acute myocardial infarction market. It is used to prevent or improve symptoms in people who've abnormal coronary heart rhythm, Chest ache, coronary heart assaults, coronary heart failure, migraine, and kinds of tremors. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the post acute myocardial infarction market in the forecast period 2022-2029. The expected CAGR of post acute myocardial infarction market is tend to be around 6.4% in the mentioned forecast period. The market was valued at USD 1816.8 million in 2021, and it would grow upto USD 2984.28 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Post Acute Myocardial Infarction Market Scope and Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Million, Volumes in Units, Pricing in USD
Drug Class (Antiplatelet Therapy, Beta Blockers, Renin-Angiotensin-Aldosterone System Inhibitors, Statin Therapy, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
F. Hoffmann-La Roche Ltd (Switzerland), Fresenius Kabi AG (Germany), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Zydus Group (India), Pfizer Inc (U.S.), Lupin (India), GSK Plc (U.K.), Glenmark Pharmaceuticals Inc (India), Amneal Pharmaceuticals (U.S.), Alnylam Pharmaceuticals, Inc (U.S.), DAIICHI SANKYO COMPANY, LIMITED (Japan)
Post-acute myocardial infarction is the most common complication of acute myocardial infarction, defined as acute coronary artery closure. It is associated with either rupture of the plaque which leading to acute onset of thrombus formation and certain arrest of blood supply to the particular area. The most frequently witnessed mechanical complications are acute mitral regurgitation secondary to papillary muscle rupture, pseudoaneurysm, ventricular septal defect, and free wall rupture.
Global Post Acute Myocardial Infarction Market Dynamics
- Increase in Cardiovascular Diseases
According to the WHO, around 60% - 85% of the population have adopted a sedentary life. According to CDC, approximately 31 million adults aged over 50 years live a sedentary life, and only 1 out of 4 U.S. adults meet the appropriate need of physical activity. This boost the market growth.
- Rising Demand for Antibiotics
The increasing demand of different antibiotics resulted in the increase in the market growth. Novel antithrombotics such as NOACs and antiplatelet drugs such as Effient offer substantial advantages, such as target specificity. Some of the major examples under this category include edoxaban (LIXIANA), rivaroxaban, and apixaban (ELIQUIS). It has been observed that Andexxa by Portola Pharmaceuticals is the first and only antidote indicated for the treatment of uncontrolled bleeding caused by rivaroxaban and apixaban.
- Rising Prevalence of Hypertension
As per the American College of Cardiology, older adults are mostly undertreated for high blood pressure, despite having the maximum prevalence of hypertension and the highest risk of CV morbidity and mortality (BP). According to the National Health and Nutrition Examination Survey (NHANES) records in the U.S., hypertension affects 70% of persons over 65 years. As our population ages, this figure will continue to rise. In 2014, 15% of the US population was 65 years old, and that number is projected to rise to 20% by 2050. This will create more opportunities for the market growth as the demand for the blockers also increases.
- Increased Product Launches
The rising product launches are adding in much to the growth of the market. The growing number of product approvals and launches is expected to boost the growth of the global myocardial infarction market. For instance, on October 13, 2020, Cadila Pharmaceuticals Ltd., launched Tikacad, which is an antiplatelet drug containing ticagrelor. It is a P2Y12 platelet inhibitor that is believed to reducte the cardiovascular death rate, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or history of myocardial infarction (MI).
- Increase in Sale of Expired Products
Generic drugs are allowed for sale after the expiry of the original branded drug. Thus, generic drugs have relatively lower prices than branded drugs. Thus, the loss of patent exclusivities is a major challenge for the manufacturers of branded drugs since it provides fair opportunities for the development of generic drugs.
- Side Effects of Cardioselective Beta Blockers
There are various side effects associated with post acute myocardial infarction drugs such as upset stomach, nausea, diarrhea or constipation, and erectile dysfunction when taking beta-blockers that hamper the market growth.
This global post acute myocardial infarction market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global post acute myocardial infarction market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Post Acute Myocardial Infarction Market
The COVID-19 pandemic faced a moderately great impact on the market growth. Hypertension is one of the most common phenomenon in COVID-19 patients; thus, beta-blockers are widely used. In addition to this, the pandemic is interrupting the medical supply chain, and the delivery of the prooducts. There is increased heart problems after the implementation of COVID vaccines. Thousands of heart diseases such as myocarditis and pericarditis are reported. But in the post pandemic era, the market is rising as the hospitals and clinics are free from the tedious responsibilities of COVID-19 patients. Thus, the market will undergo growth during the forecast period.
Global Post Acute Myocardial Infarction Market Scope
The global post acute myocardial infarction market is segmented on the basis of drug class, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Antiplatelet Therapy
- Beta Blockers
- Renin-Angiotensin-Aldosterone System Inhibitors
- Angiotensin-converting enzyme inhibitors (ACEIs)
- Angiotensin II receptor blockers (ARBs)
- Statin Therapy
- Specialty Clinics
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Post Acute Myocardial Infarction Market Regional Analysis/Insights
The global post acute myocardial infarction market is analyzed and market size insights and trends are provided by drug class, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global post acute myocardial infarction market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for global post acute myocardial infarction market throughout the forecasted period due to the high prevalence of myocardial infarction and technological advancement in the treatment.
Asia-Pacific dominates the market due to the vulnerable aging population as this group are highly susceptible to cardiovascular disorders.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Post Acute Myocardial Infarction Market Share Analysis
The global post acute myocardial infarction market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global post acute myocardial infarction market
Key players operating in the global post acute myocardial infarction market include:
- F. Hoffmann-La Roche Ltd (Switzerland)
- Fresenius Kabi AG (Germany)
- Bayer AG (Germany)
- Sun Pharmaceutical Industries Ltd (India)
- Novartis AG (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Zydus Group (India)
- Pfizer Inc (U.S.)
- Lupin (India)
- GSK Plc (U.K.)
- Glenmark Pharmaceuticals Inc (India)
- Amneal Pharmaceuticals (U.S.)
- Alnylam Pharmaceuticals, Inc (U.S.)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)